Thrombolysis and myocardial salvage. Results of clinical trials and the animal paradigm--paradoxic or predictable?
- 1 July 1993
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 88 (1) , 296-306
- https://doi.org/10.1161/01.cir.88.1.296
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Thrombolysis for Acute Myocardial Infarction: Making Sense of The Clinical Trials DataJournal of Interventional Cardiology, 1992
- ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarctionPublished by Elsevier ,1992
- Overview of patency as an end point of thrombolytic therapyThe American Journal of Cardiology, 1991
- In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparinThe Lancet, 1990
- Role of the emergency department in decreasing the time to thrombolytic therapy in acute myocardial infarctionClinical Cardiology, 1990
- Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS studyThe Lancet, 1990
- From myocardial salvage to patient salvage in acute myocardial infarction: The role of reperfusion therapyJournal of the American College of Cardiology, 1989
- TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1988
- Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial InfarctionNew England Journal of Medicine, 1983